Romesh R. Subramanian
Director/Board Member at Ceptur Therapeutics, Inc.
Romesh R. Subramanian active positions
| Companies | Position | Start | End |
|---|---|---|---|
Ceptur Therapeutics, Inc.
 Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Director/Board Member | 2022-03-20 | - |
Career history of Romesh R. Subramanian
Former positions of Romesh R. Subramanian
| Companies | Position | Start | End |
|---|---|---|---|
Ascidian Therapeutics, Inc.
 Ascidian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA. | Chief Executive Officer | 2022-10-11 | 2023-11-07 |
| President | 2022-10-11 | 2023-11-07 | |
| DYNE THERAPEUTICS, INC. | Director/Board Member | 2018-10-31 | 2019-09-30 |
| Chief Executive Officer | 2018-10-31 | 2019-09-30 | |
| Chief Tech/Sci/R&D Officer | 2019-09-30 | 2021-06-01 | |
| Founder | 2017-11-30 | 2021-06-01 | |
| President | 2018-10-31 | 2019-09-30 | |
| Corporate Secretary | 2018-10-31 | 2019-09-30 | |
| Treasurer | 2018-10-31 | 2019-09-30 | |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2014-05-31 | 2017-09-30 |
| TRANSLATE BIO, INC. | Director/Board Member | 2011-04-30 | 2014-05-31 |
| Founder | 2011-04-30 | 2014-05-31 |
Training of Romesh R. Subramanian
| Duke University | Graduate Degree |
| Emory University | Doctorate Degree |
| Loyola College (India) | Undergraduate Degree |
Statistics
International
| United States | 8 |
| India | 2 |
Operational
| Director/Board Member | 3 |
| Founder | 2 |
| Chief Executive Officer | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Ascidian Therapeutics, Inc.
Ascidian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA. | Health Technology |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Health Technology |
